It is noteworthy that Galectin 9 (Gal-9) and galectin 3 (Gal-3) can interact with PD-1 and thus are emerging targets for cancer immunotherapy in different combinations (9–12) (Figure 1). This evidence concerns the gene LGALS9 and cancer.